Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer
结合循环肿瘤 DNA (ctDNA) 和肿瘤负荷磁共振成像 (MRI) 测量来预测新辅助治疗的早期乳腺癌的反应和结果的策略
基本信息
- 批准号:10523117
- 负责人:
- 金额:$ 65.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-03 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:AdjuvantAdjuvant ChemotherapyAdjuvant StudyAdjuvant TherapyBiological AssayBiological MarkersBloodBreastBreast Cancer PatientBreast-Conserving SurgeryCancer BurdenCharacteristicsClinicalClinical TrialsCorrelative StudyDNA analysisDataDetectionDiagnosisDiseaseDisease-Free SurvivalDistantDrug EvaluationERBB2 geneEligibility DeterminationExposure toFunctional Magnetic Resonance ImagingGenetic FingerprintingsGenomicsGoalsHormone ReceptorImageIn complete remissionInfrastructureMagnetic Resonance ImagingMeasuresMetastatic toMetastatic/RecurrentModalityMolecularMonitorMutationNeoadjuvant TherapyNodalOperative Surgical ProceduresOutcomePathologicPatient riskPatient-Focused OutcomesPatientsPerformancePrediction of Response to TherapyPrimary NeoplasmProbabilityRandomizedRecurrenceResidual CancersResidual NeoplasmRiskRisk AssessmentRisk MarkerSerial Magnetic Resonance ImagingTestingTherapeuticTimeToxic effectTreatment outcomeTumor BurdenTumor VolumeValidationadvanced diseasecancer subtypescohortcompanion diagnosticsdeep sequencingdiagnostic biomarkerdrug efficacyefficacy evaluationexperiencehigh riskimprovedimproved outcomeliquid biopsymalignant breast neoplasmmultimodalitynovel therapeuticspatient responsephase II trialpredicting responsepredictive markerpredictive toolsprimary endpointprognostic modelprognostic toolprognostic valuereal time monitoringrelapse riskresponserisk stratificationstandard of caretreatment choicetreatment responsetumortumor DNA
项目摘要
ABSTRACT/PROJECT SUMMARY
Neoadjuvant chemotherapy (NAC), which is treatment given before surgery, has become a standard-of-care
for breast cancer patients diagnosed with locally advanced disease. NAC offers a unique opportunity for real-
time monitoring of tumor response and evaluation of drug efficacy. Patients who achieve pathologic complete
response (pCR) have an excellent outcome. Thus, the challenge of NAC is to bring each patient to pCR; and,
among non-responders, to identify those with a high probability of recurring for additional therapy in the adjuvant
setting. Biomarkers that accurately predict NAC response and metastatic recurrence are key to achieving these
objectives.
We hypothesize that a multimodal approach for monitoring of tumor burden during NAC—i.e., by magnetic
resonance imaging (MRI)-based functional tumor volume (FTV) and liquid biopsy-based circulating tumor DNA
(ctDNA) analyses—can yield robust and accurate predictors of response to NAC and metastatic recurrence; and
in turn, aid in therapeutic decisions regarding escalation or de-escalation of treatment to improve patient
outcomes. Here, we propose a correlative study to the neoadjuvant I-SPY 2 TRIAL, a multicenter, adaptive
randomization phase II trial that evaluates the efficacy of novel therapies in combination with standard NAC.
Integrated within I-SPY 2, is an ongoing study that evaluates MRI FTV as predictor of response and outcome,
and an infrastructure for discovery and validation of companion diagnostic markers, including ctDNA.
The proposed study aims to: (1) perform serial ctDNA profiling in patients receiving NAC; (2) combine serial
ctDNA profiles with available FTV data to develop breast cancer subtype-specific predictors of pCR, and (3) build
prognostic models that combine ctDNA and FTV information to improve on the predictive performance of residual
cancer burden (RCB) assessed at surgery.
The deliverables of this proposed study include: (1) serial ctDNA profiles in a large cohort of early breast
cancer patients; (2) a prediction tool that will calculate the probability of pCR (or residual cancer burden, RCB
0) at an early time point during treatment, and (3) a prognostic tool that will provide accurate risk assessment
for early metastatic recurrence in patients who have residual disease after NAC (non-pCR or RCB 1/2/3).
Our ultimate goal is to use the pCR prediction tool in the clinical trial setting to identify good responders who
may be eligible for early surgical treatment to reduce exposure to toxicities from unnecessary additional
therapies; and poor responders who may benefit from a switch in therapy to increase the likelihood of achieving
a pCR. Furthermore, we envision that the prognostic tool developed here will help guide treatment choices in
the adjuvant trial setting by providing aggressive adjuvant therapies to patients who are at high-risk of early
metastatic recurrence, while de-escalating or forgoing further treatment for those who were potentially cured by
NAC and surgical treatment and, therefore, not likely to recur.
摘要/项目总结
新辅助化疗(NAC),即手术前给予的治疗,已成为一种标准治疗
用于诊断为局部晚期疾病的乳腺癌患者。南汽提供了一个独特的机会,真实的-
肿瘤反应的时间监测和药物疗效的评价。达到病理完全性的患者
pCR的结果非常好。因此,NAC的挑战是使每个患者达到pCR;以及,
在无应答者中,识别复发概率高的患者,以进行辅助治疗
设置.准确预测NAC反应和转移复发的生物标志物是实现这些目标的关键
目标.
我们假设在NAC期间监测肿瘤负荷的多模式方法-即,通过磁
基于共振成像(MRI)的功能性肿瘤体积(FTV)和基于液体活检的循环肿瘤DNA
(ctDNA)分析-可以产生对NAC的响应和转移复发的稳健且准确的预测因子;以及
进而有助于关于治疗升级或降级的治疗决定,以改善患者
结果。在这里,我们提出了一个相关的研究,新辅助I-SPY 2试验,一个多中心,适应性
随机化II期试验,评估新疗法与标准NAC联合的疗效。
整合在I-SPY 2中,是一项正在进行的研究,评价MRI FTV作为反应和结局的预测因子,
以及用于发现和验证伴随诊断标志物(包括ctDNA)的基础设施。
本研究旨在:(1)对接受NAC治疗的患者进行连续ctDNA分析;(2)联合收割机连续
ctDNA谱与可用的FTV数据,以开发乳腺癌亚型特异性pCR预测因子,以及(3)构建
结合联合收割机ctDNA和FTV信息的预测模型,以提高残差的预测性能
在手术时评估的癌症负荷(RCB)。
这项拟议研究的成果包括:(1)在一个大型的早期乳腺癌患者队列中的连续ctDNA图谱,
癌症患者;(2)将计算pCR(或残余癌症负荷,RCB)概率的预测工具
0)在治疗期间的早期时间点,和(3)将提供准确风险评估的预后工具
NAC后有残留疾病的患者(非pCR或RCB 1/2/3)的早期转移性复发。
我们的最终目标是在临床试验中使用pCR预测工具来识别良好的应答者,
可能有资格接受早期手术治疗,以减少不必要的额外毒性暴露。
治疗;以及可能受益于治疗转换以增加实现
pCR。此外,我们设想,这里开发的预后工具将有助于指导治疗选择,
辅助试验环境,为早期高风险患者提供积极的辅助治疗
转移性复发,而对于那些可能通过以下方法治愈的患者,
NAC和手术治疗,因此,不太可能复发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wen Li其他文献
Wen Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wen Li', 18)}}的其他基金
Placental barrier culture to delineate the mechanism of hepatitis E virus infection at the maternal and fetal interface
胎盘屏障培养描绘母体和胎儿界面戊型肝炎病毒感染的机制
- 批准号:
10716971 - 财政年份:2023
- 资助金额:
$ 65.68万 - 项目类别:
A Neurosensory Account of Posttraumatic Stress Disorder
创伤后应激障碍的神经感觉学解释
- 批准号:
10607183 - 财政年份:2023
- 资助金额:
$ 65.68万 - 项目类别:
Deficient inhibition underlies salience network hyperactivity in stress and anxiety
抑制不足是压力和焦虑中显着网络过度活跃的基础
- 批准号:
10377665 - 财政年份:2022
- 资助金额:
$ 65.68万 - 项目类别:
Deficient inhibition underlies salience network hyperactivity in stress and anxiety
抑制不足是压力和焦虑中显着网络过度活跃的基础
- 批准号:
10559649 - 财政年份:2022
- 资助金额:
$ 65.68万 - 项目类别:
Microfabricated all-diamond microelectrode arrays for neurotransmitter sensing and extracellular recording
用于神经递质传感和细胞外记录的微加工全金刚石微电极阵列
- 批准号:
10337137 - 财政年份:2020
- 资助金额:
$ 65.68万 - 项目类别:
Microfabricated all-diamond microelectrode arrays for neurotransmitter sensing and extracellular recording
用于神经递质传感和细胞外记录的微加工全金刚石微电极阵列
- 批准号:
10563205 - 财政年份:2020
- 资助金额:
$ 65.68万 - 项目类别:
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer
结合循环肿瘤 DNA (ctDNA) 和肿瘤负荷磁共振成像 (MRI) 测量来预测新辅助治疗的早期乳腺癌的反应和结果的策略
- 批准号:
10311505 - 财政年份:2020
- 资助金额:
$ 65.68万 - 项目类别:
Enhancing CNS Drug Delivery By Manipulating The Blood-Brain Barrier
通过操纵血脑屏障增强中枢神经系统药物输送
- 批准号:
8384079 - 财政年份:2012
- 资助金额:
$ 65.68万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 65.68万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 65.68万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 65.68万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 65.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 65.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 65.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 65.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 65.68万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 65.68万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 65.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)